Pathogen Reduction Technologies and Their Impact on Metabolic and Functional Properties of Treated Platelet Concentrates: A Systematic Review
- 17 October 2022
- journal article
- review article
- Published by Georg Thieme Verlag KG in Seminars in Thrombosis and Hemostasis
- Vol. 49 (05) , 523-541
Abstract
Pathogen reduction technologies (PRTs) such as Mirasol and Intercept were developed to eliminate transfusion-transmitted infections. The impact of PRTs on platelet function during the storage period, their effect on platelet storage lesions, and the optimal storage duration following PRTs have not been clearly defined. The aim of this study was to systematically review the existing literature and investigate the impact of PRTs on functional alterations of PRT-treated platelets during the storage period. The authors identified 68 studies suitable to be included in this review. Despite the high heterogeneity in the literature, the results of the published studies indicate that PRTs may increase platelet metabolic activity, accelerate cell apoptosis, and enhance platelet activation, which can subsequently lead to a late exhaustion of activation potential and reduced aggregation response. However, these effects have a minor impact on platelet function during the early storage period and become more prominent beyond the fifth day of the storage period. Large in vivo trials are required to evaluate the effectiveness of PRT-treated platelets during the storage period and investigate whether their storage can be safely extended to more than 5 days, and up to the traditional 7-day storage period. * These authors contributed equally to this work. Article published online: 17 October 2022 © 2022. Thieme. All rights reserved. Thieme Medical Publishers, Inc. 333 Seventh Avenue, 18th Floor, New York, NY 10001, USAKeywords
This publication has 70 references indexed in Scilit:
- Treatment of Buffy Coat Platelets in Platelet Additive Solution with the Mirasol® Pathogen Reduction Technology SystemTransfusion Medicine and Hemotherapy, 2013
- Cell quality of apheresis‐derived platelets treated with riboflavin‐ultraviolet light after resuspension in platelet additive solutionTransfusion, 2011
- Pathogen Inactivation of Platelet and Plasma Blood Components for Transfusion Using the INTERCEPT Blood SystemTMTransfusion Medicine and Hemotherapy, 2011
- In vitro assessment of apheresis and pooled buffy coat platelet components suspended in plasma and SSP+ photochemically treated with amotosalen and UVA for pathogen inactivation (INTERCEPT Blood System™)Vox Sanguinis, 2010
- In vitro cell quality of buffy coat platelets in additive solution treated with pathogen reduction technologyTransfusion, 2010
- Annexin V Release and Transmembrane Mitochondrial Potential during Storage of Apheresis-Derived Platelets Treated for Pathogen ReductionTransfusion Medicine and Hemotherapy, 2010
- Preparation, storage and quality control of platelet concentratesTransfusion and Apheresis Science, 2009
- Evaluation of White Blood Cell- and Platelet-Derived Cytokine Accumulation in MIRASOL-PRT-Treated PlateletsTransfusion Medicine and Hemotherapy, 2009
- Evaluation of Different Preparation Procedures of Pathogen Reduction Technology(Mirasol®)-Treated Platelets Collected by PlateletpheresisTransfusion Medicine and Hemotherapy, 2009
- Annexins I to VIBlood Coagulation & Fibrinolysis, 1992